vs
ANTERO RESOURCES Corp（AR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ANTERO RESOURCES Corp的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity同比增速更快（5.9% vs -30.5%），ANTERO RESOURCES Corp自由现金流更多（$235.6M vs $161.8M），过去两年ANTERO RESOURCES Corp的营收复合增速更高（17.6% vs 9.0%）
Antero Resources Corporation是一家美国油气勘探企业，注册地为特拉华州，总部设于科罗拉多州丹佛市。公司全部油气储量均位于阿巴拉契亚盆地，采用水力压裂技术开展开采作业，深耕北美本土油气资源开发领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AR vs RVTY — 直观对比
营收规模更大
AR
是对方的1.8倍
$772.1M
营收增速更快
RVTY
高出36.3%
-30.5%
自由现金流更多
AR
多$73.8M
$161.8M
两年增速更快
AR
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 20.1% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | -30.5% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $978.7M | $691.7M |
净利润ARRVTY
| Q1 26 | — | — | ||
| Q4 25 | $202.9M | $98.4M | ||
| Q3 25 | $85.6M | $46.7M | ||
| Q2 25 | $166.6M | $53.9M | ||
| Q1 25 | $219.5M | $42.2M | ||
| Q4 24 | $158.8M | $94.6M | ||
| Q3 24 | $-25.2M | $94.4M | ||
| Q2 24 | $-74.6M | $55.4M |
毛利率ARRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ARRVTY
| Q1 26 | 20.1% | — | ||
| Q4 25 | 20.5% | 14.5% | ||
| Q3 25 | 9.7% | 11.7% | ||
| Q2 25 | 15.8% | 12.6% | ||
| Q1 25 | 20.1% | 10.9% | ||
| Q4 24 | 4.9% | 16.3% | ||
| Q3 24 | -2.4% | 14.3% | ||
| Q2 24 | -8.2% | 12.4% |
净利率ARRVTY
| Q1 26 | — | — | ||
| Q4 25 | 14.4% | 12.7% | ||
| Q3 25 | 7.1% | 6.7% | ||
| Q2 25 | 12.8% | 7.5% | ||
| Q1 25 | 16.2% | 6.4% | ||
| Q4 24 | 13.6% | 13.0% | ||
| Q3 24 | -2.4% | 13.8% | ||
| Q2 24 | -7.6% | 8.0% |
每股收益（稀释后）ARRVTY
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.63 | $0.86 | ||
| Q3 25 | $0.24 | $0.40 | ||
| Q2 25 | $0.50 | $0.46 | ||
| Q1 25 | $0.66 | $0.35 | ||
| Q4 24 | $0.48 | $0.77 | ||
| Q3 24 | $-0.11 | $0.77 | ||
| Q2 24 | $-0.26 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $7.6B | $7.3B |
| 总资产 | $13.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资ARRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务ARRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ARRVTY
| Q1 26 | $7.6B | — | ||
| Q4 25 | $7.6B | $7.3B | ||
| Q3 25 | $7.3B | $7.4B | ||
| Q2 25 | $7.3B | $7.6B | ||
| Q1 25 | $7.2B | $7.6B | ||
| Q4 24 | $7.0B | $7.7B | ||
| Q3 24 | $7.0B | $7.9B | ||
| Q2 24 | $7.0B | $7.9B |
总资产ARRVTY
| Q1 26 | $13.2B | — | ||
| Q4 25 | $13.2B | $12.2B | ||
| Q3 25 | $12.9B | $12.1B | ||
| Q2 25 | $12.8B | $12.4B | ||
| Q1 25 | $13.0B | $12.4B | ||
| Q4 24 | $13.0B | $12.4B | ||
| Q3 24 | $13.2B | $12.8B | ||
| Q2 24 | $13.4B | $13.4B |
负债/权益比ARRVTY
| Q1 26 | 0.19× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $457.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $235.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 17.4% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ARRVTY
| Q1 26 | $457.7M | — | ||
| Q4 25 | $370.7M | $182.0M | ||
| Q3 25 | $310.1M | $138.5M | ||
| Q2 25 | $492.4M | $134.3M | ||
| Q1 25 | $457.7M | $128.2M | ||
| Q4 24 | $278.0M | $174.2M | ||
| Q3 24 | $166.2M | $147.9M | ||
| Q2 24 | $143.5M | $158.6M |
自由现金流ARRVTY
| Q1 26 | $235.6M | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率ARRVTY
| Q1 26 | 17.4% | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度ARRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率ARRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.83× | 1.85× | ||
| Q3 25 | 3.62× | 2.97× | ||
| Q2 25 | 2.96× | 2.49× | ||
| Q1 25 | 2.09× | 3.03× | ||
| Q4 24 | 1.75× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AR
| Natural gas sales | $780.0M | 58% |
| Natural gas liquids sales | $561.4M | 42% |
| Oil sales | $50.3M | 4% |
| Other revenue and income | $818.0K | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
